Mohoni told CNBC-TV18, "Now Ranbaxy is at a two-year high and this was a stock that was at couple of years low not so long ago. So this has clearly changed its long-term trend into an uptrend and these sorts of trends tend to persist for a while. So I think it is a very good hold at the moment."
